Novel TGFβ-directed therapy approach that exclusively targets tumour cells
| Reference number | |
| Coordinator | MetaCurUm Biotech AB |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | November 2024 - May 2026 |
| Status | Completed |
| Venture | Acceleration of deep tech companies |
| Call | Acceleration of deep tech companies 2024 |
Important results from the project
We have met the project objectives and followed the project plan. We have successfully validated the quality of a fully human antibody (IgG) for preclinical studies. We have conducted initial tox/tolerability studies and set up a sensitive ELISA to measure IgG. We have conducted scientific advice with the Swedish Medical Products Agency. The work with the patent firm to investigate FTO is ongoing with follow-up investigations but no obstacles have been encountered so far.
Expected long term effects
A successful project can offer a completely new form of treatment to seriously ill cancer patients with a poor prognosis, improve quality of life and prolong life, and reduce suffering from painful metastases. By implementing the described activities, we reduce the risk of continued development of the product and significantly increase the opportunities to attract the capital needed from investors to carry out the upcoming activities required to implement "first in human" and reach the market.
Approach and implementation
The project was implemented based on the plan that was drawn up in consultation with Vinnova´s steering group. We have keept the schedule and implement the agreed activities that have been valuable for the company´s continued development. A certain delay in the project has occurred due to waiting time in connection with the Christmas and New Year holidays 2025-2026 to carry out one of the initial toxicology studies on rats by a CRO. We feel that the collaboration with Vinnova has worked well.